Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LIMK1 | P53667 | 4/20 | 0.59 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.59 |
| ▸ | CDK5R1 | Q15078 | 1/20 | 0.59 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.51 |
| ▸ | EGFR | P00533 | 4/20 | 0.50 |
| ▸ | HTR2C | P28335 | 1/20 | 0.48 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.47 |
| ▸ | TNKS | O95271 | 1/20 | 0.41 |
| ▸ | TNKS2 | Q9H2K2 | 1/20 | 0.41 |
| ▸ | RXFP1 | Q9HBX9 | 6/20 | 0.39 |
| ▸ | TP53 | P04637 | 3/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.39 |
| ▸ | POLB | P06746 | 2/20 | 0.38 |
| ▸ | PPARG | P37231 | 1/20 | 0.38 |
| ▸ | NCOA2 | Q15596 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | NCOA3 | Q9Y6Q9 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14090789 | 0.78 | CLK1 (0.61) | LIMK1CDK5CDK5R1EGFRPIK3CA | |
| SCHEMBL8894268 | 0.78 | LIMK1 (0.65) | LIMK1CDK5CDK5R1HRH4EGFR | |
| SCHEMBL16281240 | 0.78 | LIMK1 (0.65) | LIMK1CDK5CDK5R1HRH4EGFR | |
| SCHEMBL15746024 | 0.77 | GPR3 (0.43) | LIMK1CDK5CDK5R1HRH4EGFR | |
| SCHEMBL19162624 | 0.76 | TNKS (0.46) | LIMK1CDK5CDK5R1HRH4EGFR | |
| SCHEMBL24222727 | 0.75 | TNKS (0.45) | LIMK1CDK5CDK5R1HRH4EGFR | |
| SCHEMBL25016499 | 0.75 | TNKS (0.45) | LIMK1CDK5CDK5R1HRH4EGFR | |
| SCHEMBL7215827 | 0.75 | LIMK1 (0.65) | LIMK1CDK5CDK5R1HRH4EGFR | |
| SCHEMBL11799957 | 0.75 | LIMK1 (1.00) | LIMK1CDK5CDK5R1EGFR | |
| SCHEMBL24473255 | 0.74 | LIMK1 (0.59) | LIMK1CDK5CDK5R1HRH4EGFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10166216-B2 | Substituted triazoles useful as Axl inhibitors | RIGEL PHARMACEUTICALS, INC. (US) | 2019-01-01 | — | — | US | disclosed |
| US-20160243085-A1 | SUBSTITUTED TRIAZOLES USEFUL AS AXL INHIBITORS | MIDCAP FINANCIAL TRUST | 2016-08-25 | — | — | US | disclosed |
| US-9353126-B2 | Substituted triazoles useful as Axl inhibitors | RIGEL PHARMACEUTICALS, INC. (US) | 2016-05-31 | — | — | US | disclosed |
| US-20150072959-A1 | SUBSTITUTED TRIAZOLES USEFUL AS AXL INHIBITORS | MIDCAP FINANCIAL TRUST | 2015-03-12 | — | — | US | disclosed |
| US-8906922-B2 | Substituted triazoles useful as AXl inhibitors | RIGEL PHARMACEUTICALS, INC. (US) | 2014-12-09 | — | — | US | disclosed |
| US-20080188474-A1 | e.g. 1-phenyl-N3-(4-(2-(piperidin-1-yl)ethoxy)phenyl)-1H-1,2,4-triazole-3,5-diamine; receptor protein tyrosine kinase (AXL) antagonist; antiinflammatory, anticarcinogenic , antidiabetic agent; rheumatoid arthritis, vascular disease; breast, renal, endometrial, ovarian carcinoma, or myeloid leukemia | RIGEL PHARMACEUTICALS, INC. (US) | 2008-08-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10166216-B2 | Substituted triazoles useful as Axl inhibitors | AXL, TYRO3, MERTK | LIMK1 500/4885CDK5 317/4885CDK5R1 212/4885 |
| US-20150072959-A1 | SUBSTITUTED TRIAZOLES USEFUL AS AXL INHIBITORS | AXL, TYRO3, MERTK | LIMK1 500/4885CDK5 317/4885CDK5R1 212/4885 |
| US-20160243085-A1 | SUBSTITUTED TRIAZOLES USEFUL AS AXL INHIBITORS | AXL, TYRO3, MERTK | LIMK1 500/4885CDK5 317/4885CDK5R1 212/4885 |
| US-20080188474-A1 | e.g. 1-phenyl-N3-(4-(2-(piperidin-1-yl)ethoxy)phenyl)-1H-1,2,4-triazole-3,5-diamine; receptor protein tyrosine kinase (AXL) antagonist; antiinflammatory, anticarcinogenic , antidiabetic agent; rheumatoid arthritis, vascular disease; breast, renal, endometrial, ovarian carcinoma, or myeloid leukemia | AXL, TYRO3, FLT3 | LIMK1 807/4885CDK5 384/4885CDK5R1 285/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.